teladoc stock guide

Teladoc Health, Inc. (TDOC) — Stock

This guide explains teladoc stock (ticker: TDOC) — the publicly traded common shares of Teladoc Health, Inc., listed on the New York Stock Exchange (NYSE) — and summarizes the company’s virtual-care business (Telehealth, BetterHelp, Livongo and related services), trading basics, market data, financial and operational context, risks, and where to follow live updates. Early in this article you’ll learn how teladoc stock trades, where to find reliable quotes, and the major factors investors and observers watch for when assessing Teladoc’s performance.

Quick note: this article is descriptive and factual. It is not investment advice. For live prices and filings consult company investor relations and market-data providers.

Company overview

Teladoc Health is a U.S.-headquartered health technology company focused on delivering virtual care and remote health services. Founded in the early 2000s and headquartered in Purchase, New York, the company built one of the earliest large-scale telehealth platforms and expanded through organic growth and acquisitions. Major consumer- and enterprise-facing brands and offerings in Teladoc’s portfolio include the Teladoc virtual-care platform (primary care, urgent care, specialty consults), BetterHelp (online mental-health services), Livongo (chronic-condition management — diabetes, hypertension — acquired in 2020), and prior strategic holdings such as Advance Medical/Best Doctors (expert medical opinions). These businesses position the company across virtual primary care, mental health, chronic-condition management, and workforce health solutions.

Teladoc aims to serve individuals, employers, health systems and payers with subscription, utilization-based and enterprise contracts. Its strategy has emphasized scale, integrated digital care pathways, and cross-sell of mental-health and chronic-disease services into employer and payer relationships.

Stock identification and trading basics

• Ticker symbol: TDOC
• Exchange: NYSE (New York Stock Exchange)
• Trading currency: USD
• Typical regular trading hours: U.S. market hours (normal NYSE hours), with pre-market and after-hours sessions that may show additional price movement.

Basic share statistics that market-data sites report for teladoc stock include shares outstanding, public float, and market capitalization. These figures change over time (share issuance, buybacks, or corporate actions) so consult live data sources for the most recent counts. Major financial portals (company investor relations, Yahoo Finance, CNBC, StockAnalysis, eToro and similar providers) publish up-to-date share counts and market-cap snapshots alongside price quotes.

Key market data and quotes

A typical quote display for teladoc stock will include: real-time or delayed last trade price, day’s trading range (high/low), 52-week high and low, traded volume for the session, average daily volume (usually using a trailing 30- or 90-day average), and a beta or volatility metric. These data points are visible on platforms such as Yahoo Finance, CNBC, Robinhood, eToro and StockAnalysis.

As of Jan 24, 2026, according to the Associated Press list of most-active U.S. stocks, teladoc stock traded with the following session data: last price 6.045 USD, session high 6.18 USD, session low 6.03 USD, and session volume 2,064,408 shares (source: AP Most Active Stocks list). For live quotes consult the company investor relations site and major market-data providers; delayed or real-time access depends on the platform.

Historical price performance

Teladoc stock has experienced multiple distinct phases since listing on public markets. Key historical themes include an early growth and multiple-consolidation period, a notable valuation expansion during the telehealth adoption surge (around the global pandemic years), and subsequent volatility tied to post-pandemic utilization trends, integration of acquisitions (notably Livongo), and investor focus on profitability versus growth.

• IPO and early years: Teladoc completed its public listing and built a market presence that supported multiple capital-raising and M&A activities.
• Pandemic-era peak: Teladoc saw outsized attention and valuation expansion as demand for virtual care spiked, with the company becoming one of the more closely watched telehealth names.
• Post-peak correction and volatility: As in-person care resumed and investors rebalanced growth vs. profitability expectations, TDOC experienced material drawdowns from peak levels and intermittent rallies tied to earnings beats, cost reductions or strategic updates.

52-week highs and lows vary with market cycles; consult Yahoo Finance, CNBC or StockAnalysis for the precise rolling 52-week extremes at any given date.

Recent performance trends

Recent multi-month and year-to-date trends for teladoc stock reflect a combination of company-specific news, sector rotations, and macro factors. Teladoc shares have shown higher-than-average volatility compared with large-cap healthcare names, often moving sharply around earnings releases, guidance updates and sector headlines. Market coverage in mainstream business press and analyst notes frequently highlights multi-day moves around reported results or material corporate developments.

Short-term price volatility can be amplified by retail interest, options activity, and after-hours trading. As stated earlier, the AP most-active list for Jan 24, 2026 shows teladoc stock with session volume above two million shares and a closing-level price near 6.05 USD, illustrating regular intraday liquidity.

Financial summary

Teladoc operates at the intersection of healthcare and technology, producing revenue from subscription and utilization-based services sold to employers, health systems, insurers and individual consumers. Over recent reporting periods the company has reported multi-hundred-million to multi-billion dollars in annual revenue depending on the fiscal year and organic/acquired contributions. Historically Teladoc has invested heavily in growth, including the acquisition of Livongo, and this has been reflected in an operating profile with elevated expenses and periods of net losses.

Key balance-sheet and income-statement items that investors track for teladoc stock include revenue growth rate, gross margin, adjusted and GAAP operating profit (or loss), net income (or loss), EPS (trailing twelve months), free cash flow and cash/debt levels. For quantifiable, up-to-date revenue, net-income, EPS (TTM), cash and debt figures consult the company’s most recent SEC filings (10-Q, 10-K) and the investor-relations summaries posted on Teladoc’s website, as well as aggregated figures on Yahoo Finance, StockAnalysis and CNBC.

(Neutral summary only — this article does not provide specific buy/sell recommendations.)

Business segments and revenue drivers

Teladoc traditionally reports business performance across a set of operating segments and service lines. Core reporting buckets and revenue drivers commonly referenced by the company and analysts include:

• Integrated Care / Virtual Primary Care: Virtual primary and acute-care visits, chronic-condition management programs, and enterprise services sold to employers and health systems.
• Behavioral Health / BetterHelp: Online therapy and counseling services driven by subscription or per-session utilization; a major driver of member engagement and recurring revenue.
• Chronic Condition Management / Livongo: Remote monitoring, connected devices and data-driven coaching / clinical programs for conditions like diabetes and hypertension; revenue generated via enterprise contracts and payer arrangements.
• Other services: Expert medical opinions, specialty consults, international care coordination (Advance Medical/Best Doctors legacy services), and platform integration fees.

Principal revenue sources include enterprise contracts with employers and payers (often subscription or per-member-per-month arrangements), fee-for-service and per-visit billing, digital mental-health subscriptions, and device- or program-based revenue tied to chronic-disease management.

Recent growth drivers have included cross-selling of BetterHelp and Livongo services into enterprise accounts, expansion of virtual primary-care offerings, and partnerships with health systems. Conversely, declines or slower growth periods have reflected normalization of telehealth utilization after pandemic-related peaks, pricing pressure, and challenges in converting user engagement into profitable long-term revenue under certain contracts.

Recent corporate developments and news

Companies the size of Teladoc regularly issue press releases, hold earnings calls, and publish guidance updates that materially affect teladoc stock. Examples of recent categories of corporate news that investors watch include:

• Quarterly earnings releases and investor presentations.
• Guidance updates addressing revenue growth, margin targets, and free-cash-flow expectations.
• M&A activity (e.g., historical acquisition of Livongo and other strategic transactions) and integration milestones.
• Product launches, platform enhancements, or partnerships with payers and health systems.
• Executive changes, board updates, and corporate restructuring aimed at cost discipline.

As of Jan 24, 2026, the AP “Most Active Stocks” report listed Teladoc Health Inc. with session trading volume of 2,064,408 shares and a last trade near 6.045 USD, underscoring that teladoc stock remains actively traded in U.S. markets. For precise examples of the latest press releases and investor-day materials, consult Teladoc’s investor relations page and SEC filings.

Analyst coverage and price targets

Analyst coverage of teladoc stock varies across firms and periods. Common elements of analyst reports include:

• A consensus rating mix that may range across buy/overweight, hold/neutral, and sell/underweight recommendations depending on the timeframe and analyst viewpoints.
• Price targets that reflect differing assumptions about revenue growth, margin expansion, and the timeline for sustained profitability.
• Framing of the investment thesis around long-term demand for virtual care versus near-term execution, margin recovery, and competitive pressures.

Aggregators such as eToro, StockAnalysis, Motley Fool and CNBC summarize analyst ratings and price targets; readers should consult those platforms for a rolling consensus and individual analyst notes. Note that independent analysts may disagree widely on teladoc stock’s appropriate valuation multiple given differing expectations for growth and margin improvement.

Ownership and major shareholders

Publicly traded companies like Teladoc typically have a mix of institutional investors (mutual funds, pension funds, insurance companies), ETFs, and individual shareholders. Institutional ownership and notable insider holdings are reported in the company’s SEC filings and aggregated on market-data platforms.

Important ownership considerations for teladoc stock include:

• Institutional holders that can influence voting outcomes and liquidity.
• Insider holdings (executive officers and directors) and any recent open-market purchases or sales disclosed in Form 4 filings.
• ETF inclusion or exclusion — presence in healthcare and thematic ETFs can affect passive flows.

For exact, time-stamped ownership percentages and top holders consult the latest 13F filings (for institutional managers), company proxy statements, and the ownership tab on major financial-data websites.

Corporate governance and management

Teladoc’s governance structure includes a Board of Directors and a management team responsible for operating the business. Governance documents, the company’s proxy statement, and details on director biographies and committee assignments are published on the investor relations website and in the annual proxy filings.

Investors often watch for:

• Changes in executive leadership (CEO, CFO) and related transitions.
• Board refreshment or governance-policy updates.
• Compensation policies and performance targets disclosed in proxy statements.

The company’s official IR page and SEC filings are the authoritative sources for governance documents and management biographies.

Risks and controversies

Principal risks that regularly appear in teladoc stock discussions include:

• Competitive risk: Telehealth is a contested market with established health systems, insurers, startups and other digital-health players competing for enterprise contracts and consumer engagement.
• Reimbursement and regulatory risk: Changes in payer coverage, telehealth reimbursement policies, interstate licensing rules for clinicians, and other regulations can materially affect utilization and revenue.
• Execution and integration risk: Acquisitions and platform integrations (for example, the Livongo acquisition) carry execution complexity and integration costs that affect near-term operating performance.
• Profitability and cash-flow risk: Sustaining growth while returning to positive adjusted operating margins and free cash flow has been a focus for management and a concern for investors when losses persist.
• Privacy and security risks: Handling health data requires rigorous controls; breaches or regulatory findings could lead to reputational and financial costs.

Any ongoing litigation, regulatory inquiry, or material security incident will be disclosed in company filings and covered by major business press; investors should consult those filings and reliable news sources for updates.

Valuation metrics and investment considerations

Common valuation metrics used to analyze teladoc stock include:

• Price-to-sales (P/S) ratio — useful for high-growth firms with limited or negative earnings.
• Forward and trailing P/E ratios — often not meaningful when GAAP net losses persist; adjusted or pro-forma measures may be used where applicable.
• Enterprise value (EV) multiples such as EV / Revenue and EV / Adjusted EBITDA when positive adjusted EBITDA is reported.
• PEG ratio (price/earnings-to-growth) — if earnings projections become relevant and positive.

Investor considerations when assessing teladoc stock typically involve:

• Growth vs. profitability trade-offs: How quickly management can convert revenue growth into durable profit margins.
• Sensitivity to macro conditions and employer hiring/benefits budgets that influence contract renewals and utilization.
• The sustainability of mental-health and chronic-care services as recurring revenue drivers and their margins relative to primary-care visits.

All valuation calculations depend on up-to-date financials and analyst assumptions; use company filings and reputable data providers when performing metric-based comparisons.

Trading instruments and liquidity

Investors can access teladoc stock through common shares (TDOC) listed on the NYSE. Options on TDOC are generally available on U.S. options exchanges; liquidity for options depends on strike and expiry. In addition to spot equity exposure, some market participants use derivatives or structured products available via brokers to obtain leveraged or hedged exposure.

Average liquidity considerations: teladoc stock typically shows meaningful daily trading volume, but liquidity can fluctuate; consult average volume metrics on market-data sites. Pay attention to pre-market and after-hours trading: prices during extended sessions may diverge from regular-hours quotes and are often based on lower volume, which can exaggerate moves.

If you plan to trade teladoc stock, consider using a regulated broker or exchange platform. For users seeking a single provider referenced in this guide, Bitget offers market access and trading tools (note: platform features, supported order types and hours may vary; always verify your platform’s specifications and regulatory jurisdiction).

How to follow and research the stock

Primary sources and best practices to follow teladoc stock:

• Company investor relations: press releases, investor presentations, SEC filings (10-Q, 10-K, 8-K, and proxy statements).
• Earnings calls and transcripts: management commentary and Q&A can clarify strategy and near-term guidance.
• Major financial-data sites: Yahoo Finance, CNBC, StockAnalysis, Robinhood and eToro for aggregated quotes, analyst ratings and financial overview.
• Independent analyst reports and thematic healthcare coverage (Motley Fool, institutional research)—useful for different perspectives.
• Newswire coverage and reputable business press for event-driven updates (e.g., M&A announcements or regulatory developments).

For real-time trading, rely on your brokerage or trading platform’s live feeds; for archival or regulatory detail, consult the SEC EDGAR database and company filings.

Regulatory and legal environment

Telemedicine and digital health operate within a complex regulatory environment that affects teladoc stock materially. Key regulatory and legal factors include:

• Licensing and scope-of-practice rules for clinical providers varying by state and country, which affect where Teladoc can deliver care and how services are reimbursed.
• Reimbursement policies from public payers (Medicare, Medicaid in the U.S.) and private insurers; changes in reimbursement levels or rules can shift revenue dynamics.
• Data privacy and HIPAA (and international equivalents), where secure handling of personal health information is mandatory and a legal exposure area.
• Antitrust and competition reviews for sizable acquisitions or market arrangements.

Regulatory shifts — for example, changes in telehealth reimbursement policy — can have outsized impacts on teladoc stock by altering demand economics and enterprise contracting models.

Timeline of notable events

• Early 2000s: Founding and early telehealth platform development.
• Mid 2010s: Public listing and scaling of virtual-care services.
• 2020: Major acquisitions (notably Livongo) and surge in utilization during the global pandemic; Teladoc became a leading telehealth name.
• Post-2020: Integration of acquired assets (Livongo), expansion of BetterHelp and enterprise offerings, and episodes of high volatility as utilization normalized.
• Ongoing: Quarterly earnings, management updates and strategic initiatives to improve margins and grow recurring revenue streams.

(For a full, dated timeline with precise transaction dates and SEC filings, consult Teladoc’s investor relations materials.)

See also

• Telemedicine industry overview
• Peer companies in virtual care and digital health
• Virtual mental health market dynamics
• Healthcare technology and digital-health ETFs

References and data sources

Sources used to prepare this guide and where to find live, verifiable details on teladoc stock:

• Company investor relations materials and SEC filings (Teladoc investor relations) — authoritative filings and presentations.
• Yahoo Finance — aggregated quotes, financials and share statistics.
• Robinhood — retail-focused quote and summary pages.
• Motley Fool — company coverage and explanatory articles.
• CNBC — quote pages and business news coverage.
• eToro — market summaries and analyst aggregation.
• StockAnalysis — financial statements and ratios.
• CNN Markets — stock overview and data snapshots.
• Associated Press “Most Active Stocks” list (newswire) — session trading statistics. As of Jan 24, 2026, AP reported Teladoc Health Inc. with session volume 2,064,408 and last trade ~6.045 USD (session high 6.18, low 6.03) on the NYSE.

Notes on scope and updating

As of Jan 24, 2026, the AP list cited above reported the session-level price and volume noted earlier. Financial and market figures such as share price, market capitalization, EPS, and balance-sheet items are time-sensitive; readers should consult live market feeds and the company’s investor relations materials for the most current numbers. This article provides neutral, factual context and pointers to primary sources rather than real-time quotes.

Want to follow teladoc stock more closely? Use the company’s investor-relations page, live market-data pages, earnings-call transcripts, and reliable news outlets. To trade or monitor positions, consider a regulated trading platform such as Bitget and, for Web3 wallet needs, Bitget Wallet as appropriate. Always verify platform availability and regulatory status in your jurisdiction.

This page is informational and not investment advice. For financial decisions consult a licensed professional and primary filings.